Dr. Reddy's Laboratories Limited
RDYHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Dr. Reddy's Laboratories Limited focuses on Drug Manufacturers - Specialty & Generic services and products. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The $9.97B market capitalization puts RDY squarely in mid-cap range for its industry. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
Market Cap
$9.97B
Beta
0.24
P/E (TTM)
28.50
P/E (Fwd)
18.22
EPS (TTM)
$0.42
EPS (Fwd)
$0.66
ROE
8.8%
ROA
4.0%
Cash
$81.43B
Total Debt
$71.95B
Free CF
-$3.91B
52W Change
-15.6%
Annual Financials
Cash vs Debt
Where RDY stands vs its 150-day and 200-day moving averages
As of the August 17, 2026 close, RDY finished 8.36% below its 150-day moving average ($13.39) and 9.04% below its 200-day moving average ($13.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RDY overbought or oversold?
At the August 17, 2026 close, RDY's RSI(14) was 70.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $81.43B in cash comfortably exceeding the $71.95B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$3.91B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 8.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $245.88B (2023) to $335.93B (2026), reflecting a 37% increase over the period.
With a beta below 0.7, Dr. Reddy's Laboratories Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RDY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.